One Prescription Can Rewrite the Benefits Budget, SHARx Warns
As new treatments enter the market with six- and seven-figure prices, SHARx's Paul Pruitt says employers need to prepare for high-cost specialty-drug exposure across pharmacy and medical benefits while protecting employees' access to care.
ST. LOUIS, Nov. 17, 2026 /PRNewswire/ -- Many new prescriptions come with price tags that can eat up a large part of an employer's annual healthcare forecast. For self-funded employers, those costs are changing specialty pharmacy from a benefits-management issue into a different financial risk.
"A new therapy starts as a risk because you do not know whether someone on your plan will need it," said Paul Pruitt, Chief Growth Officer and Co-Founder of SHARx, a procurement management solution for high-cost prescription drugs. "Once a member needs ongoing therapy, that risk becomes a recurring financial obligation. The company has to find room in its budget for the cost, which can mean redirecting funds from planned operational needs or delaying other business spending while still making sure the employee can get the treatment they need."
"The best time to build an effective benefit strategy is before the claim arrives, when you still have room to evaluate the options without putting the business at risk," Pruitt said.
One Claim Can Change the Forecast
Annual pharmacy trend percentages can obscure how concentrated specialty-drug exposure has become. Sun Life's research into high-cost claims found that the frequency of claims exceeding $1 million increased 46% from 2022 through 2026. The most expensive drug treatment identified in the analysis averaged $3.6 million.
While these numbers are not representative of what every employer pays or every specialty medication costs, they illustrate why averages alone may not describe the financial exposure facing a specific employer's plan, according to Pruitt.
"Specialty medications are a recurring cost, which creates a different planning challenge from procedures or acute care," Pruitt said.
Build the Access Plan Before the Prescription Arrives
"Create a plan before the prescription arrives because options become much more limited once treatment is underway," Pruitt said. He recommends modeling different scenarios for medication needs and mapping out what your budget can tolerate.
For example, if one or more members on a health plan needs a medication that costs $250k a year – which is the average price of a new specialty medication – the CFO and benefit leaders need to be clear on what that would mean to the budget.
"We see employers who have come to the realization that there is no sustainable way to provide coverage for specialty medications that won't jeopardize the company, which is why they seek support by partnering with SHARx for their members who need affordable access to these high-cost medications."
Employers Need to See Drug Exposure Across Benefits
A review limited to pharmacy claims may miss specialty drugs paid through the medical benefit, including infused therapies. Employers also need to distinguish recurring medication costs from one-time, high-cost treatments such as cell and gene therapies, since each creates a different kind of budget exposure.
"As drug and medical benefits become more connected, CFOs and benefits leaders need to review pharmacy and medical data together," Pruitt said.
He recommends identifying where high-cost drugs are paid, which costs may recur, and what flexibility the plan has when lower-cost options are available.
"New therapies can begin as an unpredictable risk for a health plan. Once a member needs ongoing treatment, that cost can become a recurring obligation. Employers have finite resources, so they need to understand the exposure early and plan for how those costs may affect other benefits and business priorities," Pruitt said.
About SHARx
SHARx was founded to fight back against the broken system of overpriced prescription drugs. Industry pioneers Corey Durbin and Paul Pruitt built SHARx to put people before profits. With an innovative and ethical sourcing model, SHARx cuts through the waste with radical transparency, common-sense cost containment, and a member-first approach. No hidden markups. No games. Just the medications people need, delivered affordably, reliably and with dignity.
Learn more at SHARXplan.com
Sources
- Agboola, F., Wright, A., Lee, W., Phillips, M., Lin, G. A., Lee, M., & Emond, S. K. (2026, October 20). 2026 launch price and access report. Institute for Clinical and Economic Review.
https://icer.org/assessment/launch-price-and-access-drug-approvals-2022-2025/#overview - Goforth, A. (2026, October 23). Launch prices for new prescription drugs surge 35%. BenefitsPRO. benefitspro.com/2026/10/23/launch-prices-for-new-prescription-drugs-surge-35/
- Sun Life. (2026). 2026 high-cost claims and injectable drug trends report. sunlife.showpad.com/share/3vMu5SiQIrJ31CsLJSQeF Sun Life
Media Inquiries
Karla Jo Helms
JOTO PR™
727-777-4629
Jotopr.com
SOURCE SHARx


Share this article